Overall, n (%) N=67 | |
---|---|
Funding source | |
governmental | 12 (18) |
private not for profit | 3 (4) |
private for profit | 41 (61) |
Private for profit plus other source | 4 (6) |
Not funded | 3 (4) |
Not reported | 14 (21) |
Publication language | |
English | 67 (100) |
Sample size | |
Median (Q1-Q3) | 156 (74-355) |
n <200 | 39 (58) |
n ≥200 | 28 (42) |
Type of cancer | |
Participants with different cancer types | 47 (70) |
Cancer type not reported | 5 (7) |
All participants with same cancer type | 15 (22) |
Lung | 5 (33) |
Colorectal | 2 (13) |
Gynecologic | 2 (13) |
Prostate | 1 (7) |
Breast | 1 (7) |
Pancreatic | 1 (7) |
Hematological | 2 (13) |
Hematological and solid tumors | 1 (6) |
Cancer as subgroup of the study | 27 (40) |
Intervention | |
LMWH | 53 (79) |
UFH | 33 (49) |
Vitamin K antagonist | 20 (30) |
Direct thrombin inhibitors | 5 (7) |
Fondaparinux | 3 (4) |
Comparator | |
Active treatment | 47 (70) |
Placebo | 9 (13) |
No treatment | 11 (17) |